Patient Medication Instructions: What is the dosage of crizotinib?

Crizotinib is a pyrazolylpyridine derivative used as an anticancer agent. It is formulated into hard gelatin capsules, pills for oral administration. Crizotinib is a prescription drug used to treat non-small cell lung cancer (NSCLC)that is advanced or has spread to other parts of the body, a type of cancer caused by a type of cancer calledALK (anaplastic lymphoma kinase), ROS Also included in the treatment of pediatric patients 1 year of age and older with ALK-positive relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) and adult and pediatric patients with ALK-positive unresectable, relapsed or refractory inflammatory myofibroblastic tumor (IMT).

Crizotinib capsule preparations can usually be taken with or without food, and the capsules should not be chewed, crushed or split; crizotinib granules can be administered in two ways, such as pouring the contents directly into the patient's mouth, or pouring the contents into the oral administration aids provided (such as spoons, medicine cups). Deliver the granules directly into the patient's mouth via an administration aid (e.g., spoon, medicine cup). Administer immediately after administration with sufficient water to ensure that all medication is swallowed.

For ALK or ROS1-positive NSCLC, adult patients take crizotinib 250 mg twice a day; for patients who cannot swallow, granules are taken twice a day, with a total dose of 250 mg. For relapsed or refractory ALCL, children and young adults at a dose of 280 mg/m² twice daily. For unresectable, recurrent or refractory IMT, 250 mg twice daily for adults; 280 mg/m² twice daily for children. If adverse reactions occur, your doctor may adjust the dose. It may be reduced to 200 mg twice a day for the first time; to 250 mg once a day for the second time; if it is still intolerable, it is recommended to discontinue the drug.